House Dust Mite Allergy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

House dust mite  allergy  is  an  allergic  reaction  to  tiny  bugs  that  commonly  live  in  house  dust.  Symptoms  include frequent sneezing, a runny, stuffy, itchy nose and irritated eyes. Asthma and eczema can also be triggered by a dust mite  allergy.  Symptoms often  worsen  when  the  individual  comes  in  close  proximity  to  disturbed  dust.

The House Dust Mite Allergy – Drugs In Development research report provides a comprehensive  overview  on  the  therapeutics  under development for House Dust Mite Allergy, complete with analysis by stage of development, drug target, mechanism of  action  (MoA),  route  of  administration   (RoA)  and   molecule  type.  The report  also  covers   the  descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for House Dust Mite Allergy and features dormant and discontinued projects.

Key Target in the House Dust Mite Allergy Pipeline Drugs Market

The key target in the House Dust Mite Allergy pipeline drugs market is Der p 2 Allergen.

Key RoA in the House Dust Mite Allergy Pipeline Drugs Market

The key RoA in the House Dust Mite Allergy pipeline drugs market are sublingual, topical, nasal, intradermal, and subcutaneous.

House Dust Mite Allergy Pipeline Drugs Market, by RoA

House Dust Mite Allergy Pipeline Drugs Market, by RoA

To get more insights on key RoA, download a free sample report

Key Molecule Types in the House Dust Mite Allergy Pipeline Drugs Market

The key molecule types in the House Dust Mite Allergy pipeline products market are Allergenics (Allergen), DNA Vaccine, and Vaccine.

Key Molecule Types in the House Dust Mite Allergy Pipeline Drugs Market

 To get more insights on key molecule types, download a free sample report

Major Companies in the House Dust Mite Allergy Pipeline Drugs Market

The major companies in the House Dust Mite Allergy pipeline drugs market are Allergy Therapeutics Plc, ALK-Abello AS, Advagene Biopharma Co Ltd, Astellas Pharma Inc, Stallergenes   Greer   Ltd, Worg Pharmaceuticals, Roxall Medizin GmbH, and Genetic Immunity Inc.

House Dust Mite Allergy Pipeline Drugs Market, by Major Companies

House Dust Mite Allergy Pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

House Dust Mite Allergy Pipeline Drugs Market Overview

Key target Der p 2 Allergen
Key routes of administration Sublingual, Topical, Nasal, Intradermal, and Subcutaneous
Key molecule types Allergenics (Allergen), DNA Vaccine, and Vaccine
Key companies Allergy Therapeutics Plc, ALK-Abello AS, Advagene Biopharma Co Ltd, Astellas Pharma Inc, Stallergenes   Greer   Ltd, Worg Pharmaceuticals, Roxall Medizin GmbH, and Genetic Immunity Inc.

 

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of House Dust Mite Allergy
  • The pipeline guide reviews pipeline therapeutics for House Dust Mite Allergyby companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in House Dust Mite Allergy therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates House Dust Mite Allergy therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for House Dust Mite Allergy

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for House Dust Mite Allergy
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding House Dust Mite Allergypipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Advagene Biopharma Co Ltd
ALK-Abello AS
Allergy Therapeutics Plc
Astellas Pharma Inc
Genetic Immunity Inc
Roxall Medizin GmbH
Stallergenes Greer Ltd
Worg Pharmaceuticals Hangzhou Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

House Dust Mite Allergy – Overview

House Dust Mite Allergy – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

House Dust Mite Allergy – Therapeutics Assessment

Assessment by Target

Assessment by Route of Administration

Assessment by Molecule Type

House Dust Mite Allergy – Companies Involved in Therapeutics Development

Advagene Biopharma Co Ltd

ALK-Abello AS

Allergy Therapeutics Plc

Astellas Pharma Inc

Genetic Immunity Inc

Roxall Medizin GmbH

Stallergenes Greer Ltd

Worg Pharmaceuticals Hangzhou Co Ltd

House Dust Mite Allergy – Drug Profiles

AD-17002 – Drug Profile

Product Description

Mechanism Of Action

History of Events

AM-101 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ASP-2390 – Drug Profile

Product Description

Mechanism Of Action

History of Events

clustoid d. pteronyssinus – Drug Profile

Product Description

Mechanism Of Action

DermAll-HDM – Drug Profile

Product Description

Mechanism Of Action

standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract – Drug Profile

Product Description

Mechanism Of Action

History of Events

standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen extract – Drug Profile

Product Description

Mechanism Of Action

History of Events

Vaccine for Grass Pollen Allergy and House Dust Mite Allergy – Drug Profile

Product Description

Mechanism Of Action

Vaccine for House Dust Mite Allergy – Drug Profile

Product Description

Mechanism Of Action

Vaccine for House Dust Mite Allergy – Drug Profile

Product Description

Mechanism Of Action

WP-1049 – Drug Profile

Product Description

Mechanism Of Action

House Dust Mite Allergy – Dormant Projects

House Dust Mite Allergy – Discontinued Products

House Dust Mite Allergy – Product Development Milestones

Featured News & Press Releases

May 31, 2021: Positive outcome of European decentralised registration procedure for Stallergenes Greer’s sublingual house dust mite allergen immunotherapy tablet

May 04, 2020: Stallergenes Greer submits a marketing authorisation application in Europe for its sublingual house dust mite allergen immunotherapy tablet

Jan 13, 2020: New clinical trial for ALK’s house dust mite tablet paves the way for early registration in China

Jun 03, 2019: Targeted early treatment with ALKs ACARIZAX could improve allergic asthma treatment, allergy congress hears

May 31, 2019: Stallergenes Greer will be at 2019 EAACI Congress and present the results of its phase III House Dust Mites Tablet trial

Nov 20, 2018: Stallergenes Greer announces that the phase III trial for its sublingual allergy immunotherapy tablet STAGR320 to treat house dust mite-induced allergic rhinitis achieved its primary endpoint

May 29, 2018: Allergy Therapeutics – Positive new data with house-dust mite immunotherapy

Feb 21, 2018: New medicine for house dust mite allergic rhinitis and allergic asthma now available in France

Feb 16, 2018: Shionogi Got Approval of Partial Change Application in Dosage and Administration in Japan of Actair for Allergen Immunotherapy of Pediatric Allergic Rhinitis Caused by House Dust Mites

Feb 16, 2018: Torii Receives Approval for Additional Dosage and Administration for Pediatric Indication for MITICURE House Dust Mite Sublingual Tablets

Jan 11, 2018: New Treatment for House Dust Mite (HDM) – Induced Allergic Rhinitis Now Available in US

Nov 30, 2017: ALK secures pricing and reimbursement for ACARIZAX in France

Sep 26, 2017: Stallergenes Greer Advances Its House Dust Mite Allergy Pipeline With Acceptance Of Regulatory Submission And New Market Approval

Aug 21, 2017: ALK to accelerate launches of ODACTRA in the USA / ACARIZAX in Canada

Jul 27, 2017: Stallergenes Greer Announces Completion of Enrollment in Largest Phase III Study to Treat House Dust Mites Allergy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for House Dust Mite Allergy, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

House Dust Mite Allergy – Pipeline by Advagene Biopharma Co Ltd, 2022

House Dust Mite Allergy – Pipeline by ALK-Abello AS, 2022

House Dust Mite Allergy – Pipeline by Allergy Therapeutics Plc, 2022

House Dust Mite Allergy – Pipeline by Astellas Pharma Inc, 2022

House Dust Mite Allergy – Pipeline by Genetic Immunity Inc, 2022

House Dust Mite Allergy – Pipeline by Roxall Medizin GmbH, 2022

House Dust Mite Allergy – Pipeline by Stallergenes Greer Ltd, 2022

House Dust Mite Allergy – Pipeline by Worg Pharmaceuticals Hangzhou Co Ltd, 2022

House Dust Mite Allergy – Dormant Projects, 2022

House Dust Mite Allergy – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for House Dust Mite Allergy, 2022

Number of Products under Development by Companies, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

House Dust Mite Allergy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at House Dust Mite Allergy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live House Dust Mite Allergy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.